Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-03

Amarin Corp PLC (AMRN)

CEO Aaron Berg was paid $3,540,366 in fiscal year 2025, ↑ up 8.0% from fiscal year 2024, the 50th percentile of its disclosed peer group (SEC filing 0001193125-26-151417 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,540,366 ↑
Aaron Berg total, FY2025
50th
CEO pay percentile vs peers
11:1
CEO-to-median pay ratio
51.9%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Aaron Berg (President and Chief Executive Officer), FY2025 total compensation $3,540,366 (base salary $725,667) [exec_comp, SEC accession 0001193125-26-151417, filed 2026-04-10]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

AMRN's next annual pay disclosure, estimated April 10, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Aaron Berg$725,667$332,326$1,391,250$493,975$588,300$0$8,848$3,540,366
President and Chief Executive Officer
Steven Ketchum687,490429,09691,462339,564364,61008,8481,921,070
Executive Vice President, President of Research and Development and Chief Scientific Officer
David Keenan452,685357,77591,462339,564301,341073,4781,616,306
Executive Vice President, Chief Operating Officer
Jonathan Provoost484,181186,00091,462339,564257,08503,9411,362,233
Executive Vice President, Chief Legal & Compliance Officer and Secretary
Peter Fishman400,000173,75060,686225,295169,30007,9391,036,970
Senior Vice President, Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Aaron Berg$3,540,366$3,277,385$2,448,149↑ +262,981
Steven Ketchum1,921,0701,732,8272,350,567↑ +188,243
David Keenan1,616,306———
Jonathan Provoost1,362,233701,819659,264↑ +660,414
Peter Fishman1,036,970606,000—↑ +430,970

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Amarin Corp PLC's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper AMRN reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against AMRN
2 companies name AMRN as a compensation peer

Each company listed discloses AMRN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AMRN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Diane E. SullivanIndependent Director$68,842
Keith L. HornIndependent Director$71,903
Louis Sterling IIIIndependent Director$67,532
Mark DiPaoloFormer director (through FY2025)$21,435
Michael TorokIndependent Director$31,189
Odysseas KostasChair of the Board$73,577
Oliver O'ConnorFormer director (through FY2025)$32,883
Patrice BonfiglioIndependent Director$63,089
Paul CohenFormer director (through FY2025)$54,711
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Oliver O'ConnorDirector2026-04-18A838——CommonForm 4 ↗
Keith L. HornDirector2026-04-18A838——CommonForm 4 ↗
Dividend-equivalent accruals2026-04-18—5,866——7 insiders, 7 accrual rows
Diane E. SullivanDirector2026-04-18A838——CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18D403156,037CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18D403156,037CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18A838——CommonForm 4 ↗
Oliver O'ConnorDirector2026-04-18D438156,561CommonForm 4 ↗
Keith L. HornDirector2026-04-18D403156,037CommonForm 4 ↗
Diane E. SullivanDirector2026-04-18D403156,037CommonForm 4 ↗
Kostas D. OdysseasDirector2026-04-18D403156,037CommonForm 4 ↗
Kostas D. OdysseasDirector2026-04-18A838——CommonForm 4 ↗
Paul CohenDirector2026-04-18A838——CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18A838——CommonForm 4 ↗
Paul CohenDirector2026-04-18D403156,037CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26D3,1971652,271CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26A6,25000Derivative, Class A CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26A6,250——CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01D1,2641620,148CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01A3,688——CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01A2,44700Derivative, Class A CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01A3,688——CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01D1,8871630,079CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01D1,9261630,700CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01A3,688——CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01A2,447——CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01D1,2061619,224CommonForm 4 ↗
Dividend-equivalent accruals2026-08-01—313——1 insider, 1 accrual row
Peter FishmanSVP, CFO2026-08-01D155142,210CommonForm 4 ↗
Peter FishmanSVP, CFO2026-08-01A313——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 39 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Oliver O'ConnorDirector2026-04-18A838——CommonForm 4 ↗
Keith L. HornDirector2026-04-18A838——CommonForm 4 ↗
Diane E. SullivanDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Diane E. SullivanDirector2026-04-18A838——CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18D403156,037CommonForm 4 ↗
Paul CohenDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18D403156,037CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18A838——CommonForm 4 ↗
Oliver O'ConnorDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Oliver O'ConnorDirector2026-04-18D438156,561CommonForm 4 ↗
Keith L. HornDirector2026-04-18D403156,037CommonForm 4 ↗
Diane E. SullivanDirector2026-04-18D403156,037CommonForm 4 ↗
Kostas D. OdysseasDirector2026-04-18D403156,037CommonForm 4 ↗
Kostas D. OdysseasDirector2026-04-18A838——CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Paul CohenDirector2026-04-18A838——CommonForm 4 ↗
Patrice BonfiglioDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Keith L. HornDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Kostas D. OdysseasDirector2026-04-18A83800Derivative, Class A CommonForm 4 ↗
Louis Sterling IIIDirector2026-04-18A838——CommonForm 4 ↗
Paul CohenDirector2026-04-18D403156,037CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26D3,1971652,271CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26A6,25000Derivative, Class A CommonForm 4 ↗
Aaron BergPresident and CEO2026-06-26A6,250——CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01D1,2641620,148CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01A3,688——CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01A2,44700Derivative, Class A CommonForm 4 ↗
Jonathan ProvoostEVP, Chief Legal Officer2026-07-01A3,688——CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
Steven KetchumEVP, Chief Scientific Officer2026-07-01D1,8871630,079CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01D1,9261630,700CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01A3,688——CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01A2,447——CommonForm 4 ↗
David KeenanEVP, Chief Operating Officer2026-07-01A3,68800Derivative, Class A CommonForm 4 ↗
Peter FishmanSVP, CFO2026-07-01D1,2061619,224CommonForm 4 ↗
Peter FishmanSVP, CFO2026-08-01A31300Derivative, Class A CommonForm 4 ↗
Peter FishmanSVP, CFO2026-08-01D155142,210CommonForm 4 ↗
Peter FishmanSVP, CFO2026-08-01A313——CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Jonathan ProvoostOPTION2025-01-10——663,860—$339,564
Peter FishmanOPTION2025-01-10——440,460—225,295
Steven KetchumOPTION2025-01-10——663,860—339,564
Aaron BergOPTION2025-06-26——750,000—493,975
David KeenanOPTION2025-01-10——663,860—339,564
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Jonathan Provoost$0$0$339,5640.0%
Peter Fishman00225,2950.0%
Steven Ketchum00339,5640.0%
Aaron Berg00493,9750.0%
David Keenan00339,5640.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Aaron BergOption750,0000.8—
Aaron BergOption84,2401.8—
David KeenanOption84,2601.8—
Aaron BergOption8,2203.66—
Aaron BergOption174,1601.21—
Peter FishmanOption440,4600.62—
David KeenanOption12,5001.45—
David KeenanOption174,1601.21—
Jonathan ProvoostOption400,0000.75—
David KeenanOption663,8600.62—
Steven KetchumOption174,1601.21—
Steven KetchumOption8,2203.66—
Steven KetchumOption84,2401.8—
Steven KetchumOption663,8600.62—
Jonathan ProvoostOption663,8600.62—
05

Incentive-plan design — the Compensation Discussion & Analysis

Executive compensation should be directly linked both to continuous improvements in corporate performance (so-called “ pay for performance ”) and accomplishment of strategic objectives, and to align our executives’ interests with those of our shareholders by rewarding short-term and long-term performance and tying compensation to increases in shareholder value.

CEO STI target (% of salary)75%
CEO LTI target (% of salary)—
Independent consultantPearl Meyer
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-1387,198,31780,807,44017,509,84051.9%Passed
20252025-05-1388,817,07336,111,6986,716,64471.09%Passed
20242024-04-18111,449,58828,688,1213,628,09879.53%Passed
20232023-07-21116,866,03435,233,5864,934,47176.84%Passed
20222022-06-2785,564,19845,523,02253,634,85065.27%Passed
20212021-06-14102,483,11338,858,7761,587,32272.51%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1351.9%a
20252025-05-1371.09%b
20242024-04-1879.53%c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.

c. Approved under the standard stated in the filing — “As a result, abstentions and broker non-votes will have no effect on the vote outcome.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)11 : 1
CEO total compensation$3,540,366
Median employee compensation$326,639
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Odysseas KostasIndependent · Board Chair · Nominating and Corporate Governance$73,577$0$0—$0$73,577
Keith L. HornIndependent · Audit (Chair) · Remuneration · Compensation71,90300—071,903
Diane E. SullivanIndependent · Audit · Remuneration (Chair) · Compensation (Chair)68,84200—068,842
Louis Sterling IIIIndependent · Audit · Nominating and Corporate Governance (Chair)67,53200—067,532
Patrice BonfiglioIndependent · Audit · Remuneration · Compensation63,08900—063,089
Paul CohenIndependent · Nominating and Corporate Governance · Not standing for re-election · Departed during FY54,71100—054,711
Oliver O'ConnorNominating and Corporate Governance · Not standing for re-election · Departed during FY32,88300—032,883
Michael TorokIndependent · Remuneration · Compensation · Newly elected31,18900—031,189
Mark DiPaoloNot standing for re-election · Departed during FY21,43500—021,435
Aaron D. BergEmployee director—————0
09

Board fee structure and ownership guideline

Annual cash retainer—
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$485,161
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$485,161

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Amarin Corp PLC names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Amarin Corp PLC.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Harrow, Inc.2025Mark Baum$754,910$22,294,873$0$542,491$23,606,274
2Revance Therapeutics Inc.2023Mark Foley720,0008,810,7310522,72010,068,915
3Travere Therapeutics, Inc.2025Eric Dube854,2503,314,5203,309,384964,1258,457,151
4Evolus, Inc.2025David Moatazedi775,0003,886,5691,296,697429,0006,412,214
5Innoviva, Inc.2025Pavel Raifeld600,0002,649,9821,748,88205,400,197
6Xeris Biopharma Holdings Inc.2025John Shannon742,3342,848,000838,615607,9715,042,584
7Rigel Pharmaceuticals Inc.2025Raul Rodriguez787,405951,3272,241,570634,6494,658,805
8Vanda Pharmaceuticals Inc.2025Mihael Polymeropoulos965,6552,007,0000834,3263,851,468
9Amarin Corp PLC2025Aaron Berg725,6671,391,250493,975588,3003,540,366
10Esperion Therapeutics, Inc.2025Sheldon Koenig770,8331,260,000847,929639,3753,535,512
11Heron Therapeutics, Inc.2025Craig Collard689,431946,2541,352,917517,1893,516,291
12Puma Biotechnology, Inc.2025Alan Auerbach931,333551,549535,5131,027,3073,062,337
13Coherus BioSciences, Inc.2025Dennis Lanfear1,026,5450828,130869,2952,736,874
14Karyopharm Therapeutics, Inc.2025Richard Paulson770,000838,996241,544350,3502,320,902
15MacroGenics, Inc.2025Eric Risser561,56852,0001,049,386251,9002,078,854
16Ironwood Pharmaceuticals, Inc.2025Thomas McCourt867,568411,6960650,6761,948,390
17Collegium Pharmaceutical, Inc.2025Vikram Karnani875,00000835,4061,715,846

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Amarin Corp PLC107.75%Options 75 · RSU 25not disclosedPearl Meyer
Coherus BioSciences, Inc.not disclosedOption 100not disclosedAon
Collegium Pharmaceutical, Inc.127.3%RSU 70 · PSU 30Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry IndexAlpine Rewards, LLC
Esperion Therapeutics, Inc.110%not disclosednot disclosednot disclosed
Evolus, Inc.55%not disclosedNoRadford, an Aon Company
Harrow, Inc.100%not disclosedNoMercer, Inc.
Heron Therapeutics, Inc.not disclosedOption 66.67 · RSU 33.33not disclosedCompensia, Inc.
Innoviva, Inc.105%not disclosednot disclosedMeridian
Ironwood Pharmaceuticals, Inc.100%RSU 50 · PSU 50not disclosedAlpine Rewards LLC
Karyopharm Therapeutics, Inc.90%not disclosedYes — Relative TSRAlpine, WTW
MacroGenics, Inc.85%not disclosednot disclosedAlpine Rewards, LLC
Puma Biotechnology, Inc.169.7%Options 50 · RSU 50not disclosedCompensia
Revance Therapeutics Inc.96.8%PSU 100NoFW Cook
Rigel Pharmaceuticals Inc.124%Options 75 · RSU 25NoPearl Meyer
Travere Therapeutics, Inc.150%not disclosedNoAon
Vanda Pharmaceuticals Inc.108%not disclosedYes — Relative TSRWillis Towers Watson
Xeris Biopharma Holdings Inc.125%not disclosednot disclosedAon Consulting, Inc.

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Amarin Corp PLC in fiscal 2025?
As disclosed, Aaron Berg (President and Chief Executive Officer) was the highest-paid executive at Amarin Corp PLC in fiscal 2025, with total compensation of $3,540,366.
How does Amarin Corp PLC's chief executive pay compare to its disclosed peer group?
As disclosed, Aaron Berg's total compensation ranked at the 50th percentile of Amarin Corp PLC's disclosed peer group.
What is Amarin Corp PLC's CEO-to-median employee pay ratio?
As disclosed, Amarin Corp PLC's CEO-to-median employee pay ratio was 11:1.
How did shareholders vote on Amarin Corp PLC's executive compensation?
As disclosed, 51.9% of shareholders supported Amarin Corp PLC's executive compensation in the latest say-on-pay vote.
How much does Amarin Corp PLC spend in total on board compensation for fiscal 2025?
As disclosed, Amarin Corp PLC reported total board compensation of $485,161 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Aaron BergDEF 14A2026-04-100001193125-26-151417Section “2025 Summary Compensation Table”. As printed: 3,540,366. Filing ↗machine: r2 · c30 · span 991658–991667
2Section 01, Steven KetchumDEF 14A2026-04-100001193125-26-151417Section “2025 Summary Compensation Table”. As printed: 1,921,070. Filing ↗machine: r10 · c30 · span 1073899–1073908
3Section 01, David KeenanDEF 14A2026-04-100001193125-26-151417Section “2025 Summary Compensation Table”. As printed: 1,616,306. Filing ↗machine: r7 · c30 · span 1046569–1046578
4Section 01, Jonathan ProvoostDEF 14A2026-04-100001193125-26-151417Section “2025 Summary Compensation Table”. As printed: 1,362,233. Filing ↗machine: r13 · c30 · span 1106923–1106932
5Section 01, Peter FishmanDEF 14A2026-04-100001193125-26-151417Section “2025 Summary Compensation Table”. As printed: 1,036,970. Filing ↗machine: r5 · c30 · span 1024646–1024655
6Section 03, Jonathan Provoost OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t28 · r13 · c16 · span 1102785–1102792
7Section 03, Peter Fishman OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t29 · r3 · c15 · span 1159126–1159133
8Section 03, Steven Ketchum OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t29 · r5 · c15 · span 1171140–1171147
9Section 03, Aaron Berg OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t29 · r2 · c15 · span 1153126–1153133
10Section 03, David Keenan OPTIONDEF 14A2026-04-100001193125-26-151417Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. Filing ↗machine: t29 · r4 · c15 · span 1165132–1165139
11Section 07, pay ratioDEF 14A2026-04-100001193125-26-151417Section “CEO Pay Ratio”. As printed: 11 : 1. Filing ↗machine: t37 · r2 · c3 · span 1838690–1838697
12Section 08, Odysseas KostasDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 73,577. Filing ↗
13Section 08, Keith L. HornDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 71,903. Filing ↗
14Section 08, Diane E. SullivanDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 68,842. Filing ↗
15Section 08, Louis Sterling IIIDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 67,532. Filing ↗
16Section 08, Patrice BonfiglioDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 63,089. Filing ↗
17Section 08, Paul CohenDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 54,711. Filing ↗
18Section 08, Oliver O'ConnorDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 32,883. Filing ↗
19Section 08, Michael TorokDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 31,189. Filing ↗
20Section 08, Mark DiPaoloDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 21,435. Filing ↗
21Section 08, Aaron D. BergDEF 14A2026-04-100001193125-26-151417Section “Director Compensation”. As printed: 0. Filing ↗
22Section 02, Oliver O'Connor 2026-04-18Form 42026-04-210001193125-26-167112Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Keith L. Horn 2026-04-18Form 42026-04-210001193125-26-167118Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Diane E. Sullivan 2026-04-18Form 42026-04-210001193125-26-167113Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Diane E. Sullivan 2026-04-18Form 42026-04-210001193125-26-167113Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Louis Sterling III 2026-04-18Form 42026-04-210001193125-26-167114Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Paul Cohen 2026-04-18Form 42026-04-210001193125-26-167117Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Patrice Bonfiglio 2026-04-18Form 42026-04-220001193125-26-170731Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Patrice Bonfiglio 2026-04-18Form 42026-04-220001193125-26-170731Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Oliver O'Connor 2026-04-18Form 42026-04-210001193125-26-167112Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Oliver O'Connor 2026-04-18Form 42026-04-210001193125-26-167112Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Keith L. Horn 2026-04-18Form 42026-04-210001193125-26-167118Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Diane E. Sullivan 2026-04-18Form 42026-04-210001193125-26-167113Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Kostas D. Odysseas 2026-04-18Form 42026-04-210001193125-26-167119Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Kostas D. Odysseas 2026-04-18Form 42026-04-210001193125-26-167119Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Louis Sterling III 2026-04-18Form 42026-04-210001193125-26-167114Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Paul Cohen 2026-04-18Form 42026-04-210001193125-26-167117Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Patrice Bonfiglio 2026-04-18Form 42026-04-220001193125-26-170731Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Keith L. Horn 2026-04-18Form 42026-04-210001193125-26-167118Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Kostas D. Odysseas 2026-04-18Form 42026-04-210001193125-26-167119Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Louis Sterling III 2026-04-18Form 42026-04-210001193125-26-167114Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Paul Cohen 2026-04-18Form 42026-04-210001193125-26-167117Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Aaron Berg 2026-06-26Form 42026-06-300001193125-26-290834Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Aaron Berg 2026-06-26Form 42026-06-300001193125-26-290834Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Aaron Berg 2026-06-26Form 42026-06-300001193125-26-290834Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Jonathan Provoost 2026-07-01Form 42026-07-150001193125-26-304910Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Jonathan Provoost 2026-07-01Form 42026-07-150001193125-26-304910Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Steven Ketchum 2026-07-01Form 42026-07-150001193125-26-304911Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Peter Fishman 2026-07-01Form 42026-07-150001193125-26-304914Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Jonathan Provoost 2026-07-01Form 42026-07-150001193125-26-304910Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Steven Ketchum 2026-07-01Form 42026-07-150001193125-26-304911Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Steven Ketchum 2026-07-01Form 42026-07-150001193125-26-304911Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, David Keenan 2026-07-01Form 42026-07-150001193125-26-304912Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, David Keenan 2026-07-01Form 42026-07-150001193125-26-304912Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Peter Fishman 2026-07-01Form 42026-07-150001193125-26-304914Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, David Keenan 2026-07-01Form 42026-07-150001193125-26-304912Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Peter Fishman 2026-07-01Form 42026-07-150001193125-26-304914Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Peter Fishman 2026-08-01Form 42026-08-030001193125-26-330669Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Peter Fishman 2026-08-01Form 42026-08-030001193125-26-330669Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Peter Fishman 2026-08-01Form 42026-08-030001193125-26-330669Insider equity transaction reported since the proxy statement. Filing ↗
61Section 06, 2026 voteForm 8-K2026-05-150001193125-26-224771Item 5.07 · say-on-pay result. As reported: 51.9% (votes for as printed: 87,198,317). Filing ↗
62Section 06, 2025 voteForm 8-K2025-05-150000950170-25-072817Item 5.07 · say-on-pay result. As reported: 71.09% (votes for as printed: 88,817,073). Filing ↗
63Section 06, 2024 voteForm 8-K2024-04-220000950170-24-046290Item 5.07 · say-on-pay result. As reported: 79.53% (votes for as printed: 111,449,588). Filing ↗
64Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
65Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
66Section 09b board cost (computed)Computed——Cash 485,161 + equity 0 + all other 0 = 485,161, summed across the director compensation table rows.machine: formula: Σ = 485,161
67Harrow, Inc., Section 10b CEO totalDEF 14A2026-04-240001493152-26-018912CEO total compensation as printed in Harrow, Inc.'s own proxy. As printed: 23,606,274. Filing ↗machine: t87 · r1 · c26 · span 386989–386999
68Revance Therapeutics Inc., Section 10b CEO totalDEF 14A2024-03-210001479290-24-000071CEO total compensation as printed in Revance Therapeutics Inc.'s own proxy. As printed: 10,068,915. Filing ↗machine: span 884809–884819
69Travere Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-060001438533-26-000027CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523
70Evolus, Inc., Section 10b CEO totalDEF 14A2026-04-290001570562-26-000059CEO total compensation as printed in Evolus, Inc.'s own proxy. As printed: 6,412,214. Filing ↗machine: span 499358–499367
71Innoviva, Inc., Section 10b CEO totalDEF 14A2026-03-240001140361-26-010912CEO total compensation as printed in Innoviva, Inc.'s own proxy. As printed: 5,400,197. Filing ↗machine: t108 · r1 · c25 · span 555478–555487
72Xeris Biopharma Holdings Inc., Section 10b CEO totalDEF 14A2026-04-230001867096-26-000021CEO total compensation as printed in Xeris Biopharma Holdings Inc.'s own proxy. As printed: 5,042,584. Filing ↗machine: r3 · c42 · span 463532–463541
73Rigel Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-030001034842-26-000023CEO total compensation as printed in Rigel Pharmaceuticals Inc.'s own proxy. As printed: 4,658,805. Filing ↗machine: t120 · r3 · c22 · span 886059–886068
74Vanda Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-230001628280-26-026893CEO total compensation as printed in Vanda Pharmaceuticals Inc.'s own proxy. As printed: 3,851,468. Filing ↗machine: span 563696–563705
75Amarin Corp PLC (subject), Section 10b CEO totalDEF 14A2026-04-100001193125-26-151417CEO total compensation as printed in Amarin Corp PLC's own proxy. As printed: 3,540,366. Filing ↗machine: r2 · c30 · span 991658–991667
76Esperion Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-160001628280-26-025499CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. Filing ↗machine: span 423838–423847
77Heron Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-196306CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. Filing ↗machine: span 728212–728221
78Puma Biotechnology, Inc., Section 10b CEO totalDEF 14A2026-04-280001437749-26-013671CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. Filing ↗machine: t56 · r1 · c29 · span 540970–540979
79Coherus BioSciences, Inc., Section 10b CEO totalDEF 14A2026-04-200001104659-26-045251CEO total compensation as printed in Coherus BioSciences, Inc.'s own proxy. As printed: 2,736,874. Filing ↗
80Karyopharm Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-130001503802-26-000023CEO total compensation as printed in Karyopharm Therapeutics, Inc.'s own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348
81MacroGenics, Inc., Section 10b CEO totalDEF 14A2026-04-080001125345-26-000021CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. Filing ↗machine: r2 · c57 · span 494189–494198
82Ironwood Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-280001104659-26-050325CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. Filing ↗machine: r1 · c48 · span 584182–584191
83Collegium Pharmaceutical, Inc., Section 10b CEO totalDEF 14A2026-04-070001628280-26-024063CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403
84Section 10a, Esperion Therapeutics, Inc. reciprocityDEF 14A—0001628280-25-018229Esperion Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
85Section 10a, Coherus BioSciences, Inc. reciprocityDEF 14A—0001104659-26-045251Coherus BioSciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
86Section 10a, Revance Therapeutics Inc. reciprocityDEF 14A—0001479290-24-000071Revance Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
87Section 10a, Travere Therapeutics, Inc. reciprocityDEF 14A—0001438533-26-000027Travere Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
88Section 10a, Vanda Pharmaceuticals Inc. reciprocityDEF 14A—0001628280-26-026893Vanda Pharmaceuticals Inc. names Amarin Corp PLC in its own disclosed peer group (read from its most recent proxy). Filing ↗
89Section 10a, Evolus, Inc. reciprocityDEF 14A—0001570562-26-000059Evolus, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
90Section 10a, Heron Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-196306Heron Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
91Section 10a, Karyopharm Therapeutics, Inc. reciprocityDEF 14A—0001503802-26-000023Karyopharm Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
92Section 10a, Puma Biotechnology, Inc. reciprocityDEF 14A—0001437749-26-013671Puma Biotechnology, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
93Section 10a, Collegium Pharmaceutical, Inc. reciprocityDEF 14A—0001628280-26-024063Collegium Pharmaceutical, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
94Section 10a, Ironwood Pharmaceuticals, Inc. reciprocityDEF 14A—0001104659-26-050325Ironwood Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
95Section 10a, Rigel Pharmaceuticals Inc. reciprocityDEF 14A—0001034842-26-000023Rigel Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
96Section 10a, Harrow, Inc. reciprocityDEF 14A—0001493152-26-018912Harrow, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
97Section 10a, Innoviva, Inc. reciprocityDEF 14A—0001140361-26-010912Innoviva, Inc. names Amarin Corp PLC in its own disclosed peer group (read from its most recent proxy). Filing ↗
98Section 10a, MacroGenics, Inc. reciprocityDEF 14A—0001125345-26-000021MacroGenics, Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗
99Section 10a, Xeris Biopharma Holdings Inc. reciprocityDEF 14A—0001867096-26-000021Xeris Biopharma Holdings Inc.'s most recent proxy was read; its disclosed peer group does not include Amarin Corp PLC. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.